Targeting N-methyl-D-aspartate Receptors for Treatment of Neuropathic Pain

Overview

Journal Expert Rev Clin Pharmacol

Specialty Pharmacology

Date 2011 Jun 21

PMID 21686074

Citations 88

Authors

Hong-Yi Zhou

Shao-Rui Chen

Hui-Lin Pan

Affiliations

Soon will be listed here.

Abstract

Neuropathic pain remains a major clinical problem and a therapeutic challenge because existing analgesics are often ineffective and can cause serious side effects. Increased N-methyl-d-aspartate receptor (NMDAR) activity contributes to central sensitization in certain types of neuropathic pain. NMDAR antagonists can reduce hyperalgesia and allodynia in animal models of neuropathic pain induced by nerve injury and diabetic neuropathy. Clinically used NMDAR antagonists, such as ketamine and dextromethorphan, are generally effective in patients with neuropathic pain, such as complex regional pain syndrome and painful diabetic neuropathy. However, patients with postherpetic neuralgia respond poorly to NMDAR antagonists. Recent studies on identifying NMDAR-interacting proteins and molecular mechanisms of increased NMDAR activity in neuropathic pain could facilitate the development of new drugs to attenuate abnormal NMDAR activity with minimal impairment of the physiological function of NMDARs. Combining NMDAR antagonists with other analgesics could also lead to better management of neuropathic pain without causing serious side effects.

Citing Articles

Current and Evolving Concepts in the Management of Complex Regional Pain Syndrome: A Narrative Review.

Candan B, Gungor S Diagnostics (Basel). 2025; 15(3).

PMID: 39941283 PMC: 11817358. DOI: 10.3390/diagnostics15030353.

Astaxanthin has a beneficial influence on pain-related symptoms and opioid-induced hyperalgesia in mice with diabetic neuropathy-evidence from behavioral studies.

Ciapala K, Pawlik K, Ciechanowska A, Makuch W, Mika J Pharmacol Rep. 2024; 76(6):1346-1362.

PMID: 39528765 PMC: 11582234. DOI: 10.1007/s43440-024-00671-9.

Therapeutic Implication of miRNAs as an Active Regulatory Player in the Management of Pain: A Review.

Hassan M, Shahzadi S, Yasir M, Chun W, Kloczkowski A Genes (Basel). 2024; 15(8).

PMID: 39202362 PMC: 11353898. DOI: 10.3390/genes15081003.

Selective inhibitor of sodium-calcium exchanger, SEA0400, affects NMDA receptor currents and abolishes their calcium-dependent block by tricyclic antidepressants.

Boikov S, Karelina T, Sibarov D, Antonov S Front Pharmacol. 2024; 15:1432718.

PMID: 39156114 PMC: 11327140. DOI: 10.3389/fphar.2024.1432718.

FTY720/Fingolimod mitigates paclitaxel-induced Sparcl1-driven neuropathic pain and breast cancer progression.

Singh S, Weigel C, Brown R, Green C, Tuck C, Salvemini D FASEB J. 2024; 38(15):e23872.

PMID: 39126272 PMC: 11607628. DOI: 10.1096/fj.202401277R.

References

Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A . Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984; 307(5950):462-5. DOI: 10.1038/307462a0. View

Liu H, Mantyh P, Basbaum A . NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature. 1997; 386(6626):721-4. DOI: 10.1038/386721a0. View

Matsuda K, Kamiya Y, Matsuda S, Yuzaki M . Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Brain Res Mol Brain Res. 2002; 100(1-2):43-52. DOI: 10.1016/s0169-328x(02)00173-0. View

Christoph T, Reissmuller E, Schiene K, Englberger W, Chizh B . Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res. 2005; 1048(1-2):218-27. DOI: 10.1016/j.brainres.2005.04.081. View

Schwartzman R, Alexander G, Grothusen J, Paylor T, Reichenberger E, Perreault M . Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009; 147(1-3):107-15. DOI: 10.1016/j.pain.2009.08.015. View

Bennett A, Everhart A, Hulsebosch C . Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res. 2000; 859(1):72-82. DOI: 10.1016/s0006-8993(99)02483-x. View

Wang Y, Yu X, Salter M . Ca(2+)-independent reduction of N-methyl-D-aspartate channel activity by protein tyrosine phosphatase. Proc Natl Acad Sci U S A. 1996; 93(4):1721-5. PMC: 40009. DOI: 10.1073/pnas.93.4.1721. View

Townsend M, Yoshii A, Mishina M, Constantine-Paton M . Developmental loss of miniature N-methyl-D-aspartate receptor currents in NR2A knockout mice. Proc Natl Acad Sci U S A. 2003; 100(3):1340-5. PMC: 298774. DOI: 10.1073/pnas.0335786100. View

Raymond L, Tingley W, Blackstone C, Roche K, Huganir R . Glutamate receptor modulation by protein phosphorylation. J Physiol Paris. 1994; 88(3):181-92. DOI: 10.1016/0928-4257(94)90004-3. View

10.

Hollmann M, Boulter J, Maron C, Beasley L, Sullivan J, Pecht G . Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron. 1993; 10(5):943-54. DOI: 10.1016/0896-6273(93)90209-a. View

11.

Sanz-Clemente A, Matta J, Isaac J, Roche K . Casein kinase 2 regulates the NR2 subunit composition of synaptic NMDA receptors. Neuron. 2010; 67(6):984-96. PMC: 2947143. DOI: 10.1016/j.neuron.2010.08.011. View

12.

Liu H, Wang H, Sheng M, Jan L, Jan Y, Basbaum A . Evidence for presynaptic N-methyl-D-aspartate autoreceptors in the spinal cord dorsal horn. Proc Natl Acad Sci U S A. 1994; 91(18):8383-7. PMC: 44610. DOI: 10.1073/pnas.91.18.8383. View

13.

Qu X, Cai J, Li M, Chi Y, Liao F, Liu F . Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp Neurol. 2008; 215(2):298-307. DOI: 10.1016/j.expneurol.2008.10.018. View

14.

Eisenberg E, LaCross S, Strassman A . The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Neurosci Lett. 1995; 187(1):17-20. DOI: 10.1016/0304-3940(95)11326-r. View

15.

Soto D, Pancetti F, Marengo J, Sandoval M, Sandoval R, Orrego F . Protein kinase CK2 in postsynaptic densities: phosphorylation of PSD-95/SAP90 and NMDA receptor regulation. Biochem Biophys Res Commun. 2004; 322(2):542-50. DOI: 10.1016/j.bbrc.2004.07.158. View

16.

Jones M, Leonard J . PKC site mutations reveal differential modulation by insulin of NMDA receptors containing NR2A or NR2B subunits. J Neurochem. 2005; 92(6):1431-8. DOI: 10.1111/j.1471-4159.2004.02985.x. View

17.

Leung A, Wallace M, Ridgeway B, Yaksh T . Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001; 91(1-2):177-87. DOI: 10.1016/s0304-3959(00)00433-4. View

18.

Wiech K, Kiefer R, Topfner S, Preissl H, Braun C, Unertl K . A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg. 2004; 98(2):408-413. DOI: 10.1213/01.ANE.0000096002.53818.BD. View

19.

Momiyama A . Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord. J Physiol. 2000; 523 Pt 3:621-8. PMC: 2269820. DOI: 10.1111/j.1469-7793.2000.t01-1-00621.x. View

20.

Markram H, Segal M . Activation of protein kinase C suppresses responses to NMDA in rat CA1 hippocampal neurones. J Physiol. 1992; 457:491-501. PMC: 1175742. DOI: 10.1113/jphysiol.1992.sp019389. View